In the FLIPPER trial, the combination of palbociclib and fulvestrant demonstrated a potential for constipation compared to the placebo/fulvestrant cohort in postmenopausal women with HR+/HER2-advanced breast cancer (Tibau et al., 2023). Here, ERBB2 is linked to breast cancer.